Current health news covers major investments by Merck Animal Health and Gilead Sciences in the U.S., regulatory decisions ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

We expected miracles—what we got was a legal minefield. As GLP-1 drugs like Ozempic reshape bodies and bottom lines, a ...

Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

We expect disappointing results in the first quarter will be balanced by higher-than-anticipated growth in the second half.

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...